Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. by Laurberg, T et al.
1 
 
Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive 
premenopausal breast cancer patients who received adjuvant chemotherapy – results from 
two independent randomized trials. 
 
Tinne Laurberg1*, TrineTramm2*, Torsten Nielsen3, Jan Alsner1, Silje Nord4, Simen Myhre4, Therese 
Sørlie4, Samuel Leung3, Cheng Fan5, Charles Perou5, Karen Gelmon3, J Overgaard1, David Voduc3, 
Aleix Prat6,7, Maggie Chon U Cheang8,#  
1. Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark 
2. Department of Pathology, Aarhus University Hospital, Denmark 
3. British Columbia Cancer Agency, Vancouver, Canada 
4. Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Norway 
5. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, USA 
6. Department of Medical Oncology, Hospital Clinic, Barcelona, Spain 
7. Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain 
8. Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK 
* These authors contributed equally to the work 
#Corresponding author 
Maggie Chon U Cheang, PhD 
Clinical Trials and Statistics Unit at 
The Institute of Cancer Research 
London, UK 
Email: Maggie.cheang@icr.ac.uk 
Funding: This work was supported by funds from ReThink Breast Cancer Career Development 
Award for MCU Cheang, The Danish Council for Strategic Research (DBCG-TIBCAT) and CIRRO 
(Danish Center for Interventional Research in Radiation Oncology). 
Acknowledgments: We thank Sherman Lau at the Genetic Pathology Evaluation Centre 
(Vancouver) for his assistance in RNA extraction of samples from the BC trial. 
Disclosure. C.M.P, is equity stock holders of, and T.O.N. consults for BioClassifier LLC. C.M.P., 
T.O.N. and M.C.U.C. have filed a patent on the PAM50 assay.  T.T, J.A., S.M, T.S. and J.O holds a 
patent for a gene signature associated with efficacy of radiotherapy in breast cancer (international 
patent publication no. WO 2013/132354A2). The patent is not related to the present work. 
Keywords: Breast cancer, intrinsic subtypes, mastectomy, premenopausal, radiation therapy, 
randomized trial 
2 
 
 
Abstract (max 300 words) 
Background: The study of the intrinsic molecular subtypes of breast cancer has revealed differences 
among them in terms of prognosis and response to chemotherapy and endocrine therapy. However, 
the ability of intrinsic subtypes to predict benefit from adjuvant radiotherapy has only been examined 
in few studies.  
Methods: Gene expression-based intrinsic subtyping was performed in 228 breast tumors collected 
from 2 independent post-mastectomy clinical trials (British Columbia and the Danish Breast Cancer 
Cooperative Group 82b trials), where pre-menopausal patients with node-positive disease were 
randomized to adjuvant radiotherapy or not. All patients received adjuvant chemotherapy, and a 
subgroup of patients underwent ovarian ablation. Tumors were classified into intrinsic subtypes: 
Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-like using the research-based PAM50 
classifier.  
Results: In the British Columbia study, patients treated with radiation had an overall significant lower 
incidence of locoregional recurrence compared to the controls. For Luminal A tumors the risk of loco-
regional recurrence was low and was further lowered by adjuvant radiation. These findings were 
validated in the DBCG 82b study. The individual data from the two cohorts were merged, the hazard 
ratio (HR) for loco-regional recurrence associated with giving radiation was 0.34 (0.19 to 0.61) 
overall and 0.12 (0.03 to 0.52) for Luminal A tumors. 
Conclusion: In both postmastectomy trials patients with Luminal A tumors turned out to have a 
significant lower incidence of loco-regional recurrence when randomized to adjuvant radiotherapy, 
leaving no indication to omit postmastectomy adjuvant radiation in pre-menopausal high-risk patients 
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with Luminal A tumors. It was not possible to evaluate the effect of radiotherapy among the other 
subtypes because of limited sample sizes.  
Introduction: 
In the past two decades there has been a growing focus on breast tumor heterogeneity, and genomic 
studies have defined five major intrinsic subtypes of importance: Luminal A, Luminal B, Basal-like, 
HER2-enriched, and Normal-like [1,2]. Intrinsic subtype was initially discovered by global-gene 
expression profiling, later a 50-gene profile (PAM50) was developed to be applied on formalin-fixed 
paraffin-embedded tumor tissue [3], and developed as a qualitative assay that utilizes gene expression 
data, weighted together with clinical variables to generate a risk category and numerical score, to 
assess a patient's risk of distant recurrence of disease [4]  
 
The benefit of administering adjuvant radiation therapy (RT) in combination with adjuvant systemic 
chemotherapy was first demonstrated by two independent randomized trials: The British Columbia 
(BC) Randomized Radiation trial [5] and the Danish Breast Cancer Group (DBCG) protocol 82b [6].  
After 10 years of follow up, women in the DBCG 82b trial assigned to chemotherapy plus RT had a 
23% reduction in the rate of loco-regional recurrence (LRR) and a 9% reduction in mortality. A 
similar effect was demonstrated in the BC-trial after 15 years of follow-up: patients treated with RT 
had a 33% reduction of LRR and a 29% reduction in mortality from breast cancer. These findings 
have had a profound impact on the indication of RT, and all high-risk patients, particularly those with 
node involvement more than 4 positive nodes, often receive adjuvant RT regardless of tumor 
characteristics and adjuvant systemic treatment. However, there is still a substantial portion of 
patients who will develop loco-regional relapse. 
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The study of the intrinsic molecular subtypes of breast cancer has revealed differences among them 
in terms of prognosis and response to chemotherapy and endocrine therapy [7-13]. To a lesser extent 
studies have tried to clarify if intrinsic subtypes may affect the effect of RT [14-16]. 
 
Here, we aim to test if intrinsic subtypes have predictive impact on the effect of post-mastectomy RT 
among young lymph-node positive patients treated with systemic therapy.  We first tested the intrinsic 
subtypes in the BC-trial and then validated our findings in a subset of patients from the DBCG 82b 
trial.  
 
Patients and Methods: 
Patient populations 
A detailed description of the trials is found in Supplementary Table 1. The British Columbia (BC) 
trial enrolled 318 high-risk pre-menopausal patients from 1979-86 [5]. The inclusion criterion was 
pathological examined lymph-node positive disease. All patients were treated with mastectomy and 
axillary dissection; adjuvant systemic treatment was cyclophosphamide-methotrexate and 5-
flurouracil (CMF). The patients were randomized to postmastectomy RT or no RT. The dose of RT 
was 37.5 Gy (given in 16 fractions) through two tangential fields of the chest wall and 35 Gy through 
an anterior supraclavicular–axillary field with a posterior axillary boost. Finally, the internal 
mammary field received a dose of 35 Gy. All the fields were treated with cobalt-60. In addition 
patients with estrogen receptor positive tumor were sub-randomized to receive ovarian ablation 
induced by radiation and prednisolone. 20 years clinical follow-up was obtained for all patients.  
 
The DBCG 82b trial enrolled 1708 high-risk premenopausal patients from 1982-89 [6]. The inclusion 
criterion was lymph-node positive disease and/or tumor size larger than 5 cm and/or invasion of tumor 
to surrounding skin or pectoral fascia. Like the BC-trial, all patients had mastectomy, axillary 
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dissection, received adjuvant CMF and were randomized to postmastectomy RT or no RT. The 
intended dose of RT was 55 Gy (given in 25 fractions) or 53 Gy (given in 22 fractions) delivered 
through an anterior electron field to the chest wall and internal mammary nodes and an anterior photon 
field against the supraclavicular, infraclavicular, and axillary regions. The use of posterior axillary 
fields was advised in patients in whom the ratio of the anterior to posterior diameter was too large to 
limit the maximal absorbed dose. The closing date for assessment of recurrence and vital status was 
1 January, 2012. The potential median observation time was 25.1 years. 
 
Gene expression profiling 
A flowchart for the patients included is shown in Supplementary Figure 1. From the 318 enrolled 
patients in BC-trial, 159 (50%) had formalin fixed paraffin embedded (FFPE) tissues available for 
RNA extraction. The gene expression profiles of the PAM50 genes essential for intrinsic subtype 
classification were collected using Nanostring nCounter® system [13,17]. Expression of each gene 
was normalized relative to the expression of the five housekeeper genes including ACTB, MRPL19, 
PSMC4, RPLP0 and SF3A. In 145/159 cases intrinsic subtyping by PAM50 was technically 
successful.  
 
To enhance the comparability between the studies only material from DBCG 82b-patients with 
lymph-node positive disease were included. Fresh frozen tumor (FFT) samples were available from 
83 patients. Extraction of mRNA from FFT and microarray analysis was performed as described 
previously [18]. Whole gene expression profiles were obtained using the Applied Biosystem Human 
Genome Survey Microarray v2.0 (Applied Biosystem, Foster City, US). Microarray data was log2-
transformed and quantile normalized. The 83 patients are part of a previously published data set 
(GEO: GSE24117).  
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In our 148 samples, we have 49 ER positive patients, 74 ER negative patients, and 25 patients without 
ER status. To match the clinicopathological heterogeneity of the training cohort, we use all the 49 ER 
positive patients, and randomly select 49 ER negative from the 74 (subsetting), calculate the average 
expression of these 49 pairs of samples, and use this average expression as the normalization vector. 
Instead of row (gene) median centering, we subtract this normalization vector from the whole data 
matrix (148 samples), and use the residue as our normalized data matrix to perform PAM50 analysis 
[3,19].  
 
Statistical analysis 
Primary endpoint was local-regional relapse (LRR) for both trials, defined as relapse in the ipsilateral 
chest wall or an axillary, internal mammary, or supraclavicular lymph-node. Cumulative incidence 
curves for LRR were plotted using a competing risk model, considering distant metastasis and death 
as competing events. Crude hazard ratios (HR) were computed for all end-points using Cox 
proportional hazards regression. Patient and clinicopathological parameters were compared by chi-
squared test. All tests were two-tailed and p-value < 0.05 were considered significant. All statistical 
tests were performed using STATA version 12.1 (Stata Corp, College Station, Texas, USA) and R 
3.0.1.  
 
Results: 
The patient and clinicopathological parameters had a similar distribution within the randomization 
arms in both studies (Table 1). Similar distributions were also found between patients from the study 
cohorts and the original BC and DBCG 82b trials, except for lymph node status and tumor size  
(DBCG 82b) and malignancy grades (BC) (Supplementary Table 2). 
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In the BC cohort, 39% patients were assigned as Luminal A (56/145), 16% Luminal B (23/145), 17% 
HER2-E (25/145), 19% Basal-like (27/145) and 10% as Normal-like (14/145). In the DBCG 82b 
validation-cohort of 83 patients, the distribution of intrinsic subtypes was similar to the BC-study 
(P=0.94); 36% patients were assigned to Luminal A (30/83), 18% to Luminal B (15/83), 14% to 
HER2-E (12/83), 19% to Basal-like (16/83) and 12% to Normal-like (10/83) (Table 1). 
Association of Locoregional recurrence with Radiation therapy, stratified by intrinsic subtypes 
Overall, adjuvant RT decreased the locoregional recurrence significantly in both BC study and DBCG 
82b study (Figure 1). After 20 years of follow up, the cumulative incidence proportion of LRR was 
15% in the BC trial among women assigned to RT compared to 36% in the control group, giving a 
22% (95CI: 8-36%) absolute risk reduction of LRR associated to RT (HR = 0.35 (0.17-0.72). A 
similar effect was demonstrated in the DBCG 82b trial, wherein the 20-years risk of LRR was 11 % 
in the RT arm vs 37% in the control, giving a 26% (8-44%) absolute LRR risk reduction, HR = 0.30 
(0.11-0.83). In the BC study, patients with Luminal A tumors had a significant reduced risk of LRR 
(4% in the RT arm vs 31% in the control arm) when treated with RT, giving a 20-years absolute LRR 
risk difference of 27% (9-46%), HR = 0.17 (0.01-0.92)  (Figure 2).  A reduction of LRR was also 
found among the Basal-like cases (Figure 3). No statistically significant difference of LRR was 
observed between the radiation- and control arm at 20 years for patients with Luminal B and the few 
HER2-E tumors, respectively (Figure 3).  
In the DBCG 82b validation-cohort, among patients with Luminal A tumors, those who received RT 
had a significantly reduced risk of LRR (6% in the RT arm vs. 42% in the control arm). The 20-years 
absolute LRR risk difference was 36% (6-66%), HR = 0.12 (0.01-1.02) (Figure 2). LRR risk 
differences did not reach statistical significance, with hazard ratio confidence intervals crossing 1.0 
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observed between the radiation- and control arm at 20 years for patients with Luminal B, Basal-like 
and HER2-E tumors respectively (Figure 3)  
An overall estimate was calculated by merging the individual data from the two trials. Adjuvant RT 
reduced the incidence of LRR significant in the merged cohort (HR = 0.33 (0.18 -0.60)) (Figure 3). 
The overall estimate within each intrinsic subtype generally favorable outcome was observed in the 
RT arm. This benefit was greatest for Luminal A (HR = 0.12 (0.02-0.60)) and to a lesser extent for 
the Basal-like tumors. In the smaller Luminal B and HER2-E tumor subsets, no significant differences 
were observed in the risk of LRR between the RT – and control arm.  
Discussion: 
We studied intrinsic subtyping of patients from the original post-mastectomy randomized radiation 
studies, BC- and DBCG 82b-trial, and confirmed that our translational study had demonstrated a 
reduced risk of LRR associated to RT among young high-risk patients treated with adjuvant systemic 
therapy as the original trials. 
Our data supports that premenopausal lymph-node positive patients with Luminal A tumors do benefit 
from postmastectomy RT. The other intrinsic subtypes generally have favorable outcomes in the RT 
arm, but because of the low numbers within each of these subgroups, it was not possible to prove the 
benefit of RT.  
On a larger material from the DBCG 82b and -c trials, molecular subtypes were approximated by an 
immuno-histochemical panel of estrogen, progesterone and HER2[20]. Luminal A-like tumors had 
beneficial effect of RT (3% in RT arm vs. 32% in the control arm), and the 15-year overall survival 
was improved from 33% vs 44%, HR = 0.78 (0.64-0.93). They did also find an equivalent (3% vs 
48%) association between RT and LRR among Luminal B-like tumors (defined as estrogen and/or 
progesterone receptor positive and HER2 positive).  
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However, Liu et al found among post-menopausal lymph-node negative patients receiving tamoxifen 
and randomized to +/- RT, that intrinsic subtype classification had prognostic impact on the risk of 
developing local failure, but was not predictive of benefit from RT(14). Interestingly, the author 
observed no effect of RT among low-risk patients older than 60 patients with Luminal A tumors. 
These opposite findings of RT effects on Luminal tumors in our study may reflect the a priori 
prognosis of the different study populations. In the current study and the Kyndi paper, the cohort 
consisted of high-risk lymph-node positive patients, whereas in the Liu study all the patients had 
lymph-node negative disease. One could speculate that in the first case the less aggressive tumor type, 
Luminal A, had beneficial effect of RT whereas it is more doubtful with the more aggressive tumor 
subtypes, because those patients suffer from distant metastases. Luminal A tumors are local slow 
growing and have such a good prognosis after adjuvant systemic treatment, that the patients do not 
develop LRR and as a consequence do not obtain any beneficial effect from RT. It is also likely that 
the Luminal A tumors harbor further heterogeneity in regard to cellular radiosensitivity. In a previous 
study, a differential effect of postmastectomy RT in Luminal A tumors has been observed, when 
examining a 7-gene profile predictive of response to postmastectomy RT (DBCG-RT profile) [16]. 
Recently, Sjøgren et al also reported no predictive value of intrinsic subtype related to RT among 
lymph-node negative patients randomized to +/- RT after breast conservative surgery, but low-risk 
patients with Luminal A tumors had beneficial effect of RT [15]. The inconsistent results of the 
subanalysis restricted to older low-risk Luminal A patients could be due to all patients receiving 
tamoxifen in the paper from Lui et al, whereas only 8% received adjuvant systemic treatment in the 
Sjøgren study. 
A limitation of our present study was the low number of patients with available material in 
comparison with the total number of patients accrued in the original trial. Another limitation is that 
at the time of enrollment in the trials the standard treatment for all premenopausal high-risk patients 
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was adjuvant CMF; if the patients were treated today they would have received anthracycline and/or 
taxane-based systemic treatment. We also acknowledge that the expression profiles were obtained 
from two different technology platforms: the expression profiles from the BC-study were based on 
FFPE-derived RNA analyzed on the Nanostring nCounter whereas that from the DBCG 82b trial was 
based on frozen-tissue derived RNA applied to whole genome microarrays. However, despite 
different gene technologies applied, the PAM50 intrinsic calls and their association of outcome to 
radiation therapy were similar in the two trials. Hence our results suggest that PAM50 assignments 
are robust across technology platforms and patient populations, as Luminal A tumors did benefit from 
RT in both studies. 
In summary, we demonstrate using material from two independent randomized trials that 
postmastectomy RT significantly decreases local-regional recurrences among pre-menopausal high-
risk patients treated with chemotherapy.  Because of limited material, when breaking into the major 
intrinsic molecular subtypes it was only possible to evaluate the effect of RT among patients with 
Luminal A tumors. In both trials, RT lowered the risk of LRR, and thus there is no molecular subtype 
indication to omit adjuvant chest wall radiation in pre-menopausal high-risk patients with Luminal A 
tumors treated by mastectomy. 
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Figure legends 
 
Figure 1. Loco-regional recurrence as a function of randomization assignment to adjuvant postmastectomy 
radiotherapy (RT) within the study cohorts of the BC-trial (left) and the DBCG 82b-trial (right). 
 
Figure 2. Loco-regional recurrence among patients with a Luminal A tumor as a function of randomization 
to adjuvant postmastectomy radiotherapy (RT) within the BC-trial (left) and the DBCG 82b-trial (right). 
 
Figure 3. Forest plot showing the association between radiotherapy (RT) and the incidence of local-
regional recurrence within different intrinsic subtype subgroups. BC-trial (Blue bar), DBCG 82b-trial (Red 
bar) and Merged data (Black bar). In subgroups with no events, HR cannot be estimated, nor can the overall 
HR.  
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Table 1. Distribution of patient and clinicopathological parameters among patients from the BC and DBCG 
82b study cohorts. 
 
 BC trial  DBCG 82b trial 
 All (%) RT  (%) NoRT (%) P-value  All  (%) RT  (%) NoRT (%) P-value 
Patients (N) 145 (100%) 69 (48%) 76 (52%)    83 (100%) 45 (54%) 38 (46%)  
Ovarian ablation  35 (24%) 19 (28%) 16 (21%) 0.36  0 (0%) 0 (0%) 0 (0%)  
Age       0.58        0.94 
 <41 41  (28%) 18 (26%) 23 (30%)   15 (18%) 8 (18%) 7 (18%)  
 41-  104 (72%) 51 (74%) 53 (70%)   68 (82%) 37 (82%) 31 (82%)  
Tumor size (mm)       0.65        0.64 
 <21  40 (28%) 16 (23%) 24 (32%)   24 (29%) 12 (27%) 12 (32%)  
 21-50  82 (57%) 41 (59%) 41 (54%)   46 (55%) 27 (60%) 19 (50%)  
 >50 9 (6%) 4 (6%) 5 (7%)   13 (16%) 6 (13%) 7 (18%)  
 Unknown  14 (10%) 8 (12%) 6 (8%)   0 (0%) 0 (0%) 0 (0%)  
Lymph node status       0.80        0.44 
 1-3 positive 84 (58%) 38 (55%) 46 (61%)   42 (51%) 21 (47%) 21 (55%)  
 >3 positive 49 (34%) 25 (36%) 24 (32%)   41 (49%) 24 (53%) 17 (45%)  
 Unkown 12 (8%) 6 (9%) 6 (8%)   0 (0%) 0 (0%) 0 (0%)  
Malignancy grade       0.53        0.78 
 Grade 1 16 (11%) 7 (10%) 9 (12%)   10 (12%) 4 (9%) 6 (16%)  
 Grade 2 51 (35%) 25 (36%) 26 (34%)   47 (57%) 26 (58%) 21 (55%)  
 Grade 3 55 (38%) 29 (42%) 26 (34%)   23 (28%) 13 (29%) 10 (26%)  
 Unknown  23 (16%) 8 (12%) 15 (20%)   3 (4%) 2 (4%) 1 (3%)  
Histopathology                 
 Ductal carcinoma 131 (90%) 63 (91%) 68 (89%) 0.71  70 (84%) 39 (87%) 31 (82%) 0.52 
 ER-pos  * 79 (54%) * 38 (55%) * 41 (54%) 0.89  55 (66%) 31 (69%) 24 (63%) 0.58 
 HER2-pos  * 22 (15%) * 14 (20%) * 8 (11%) 0.10  26 (31%) 13 (29%) 13 (34%) 0.60 
Intrinsic subtype       0.17        0.77 
 LumA 56 (39%) 26 (38%) 30 (39%)   30 (36%) 18 (40%) 12 (32%)  
 LumB 23 (16%) 10 (14%) 13 (17%)   15 (18%) 6 (13%) 9 (24%)  
 Her2-E 25 (17%) 17 (25%) 8 (11%)   12 (14%) 7 (16%) 5 (13%)  
 Basal-like 27 (19%) 12 (17%) 15 (20%)   16 (19%) 9 (20%) 7 (18%)  
 Normal-like 14 (10%) 4 (6%) 10 (13%)    10 (12%) 5 (11%) 5 (13%)  
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Figure 2 
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Figure 3 
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Supplementary Table 1. Overview of the treatment in the BC-trial and the DBCG 82b-trial. 
 
 
BC-trial DBCG 82b 
Period 1979-1986 1982-89 
Number 318 1708 
High-risk Lymph-node positive Lymph-node positive or 
Tumor > 5cm or 
Tumor infiltration in the skin or fascia 
Surgery Mastectomy and axillary dissection 
level 1 and 2 
Mastectomy and axillary dissection 
level 1 and part of level 2 
Chemotherapy  CMF  
Cyclophosphamide (600 mg) 
Methotrexate (40 mg) 
Fluorouracil (600 mg) 
CMF  
Cyclophosphamide (600 mg) 
Methotrexate (40 mg) 
Fluorouracil (600 mg) 
 Interval 3 weeks 4 wee 
 Number of cyclus 17 (1979-80) or 8-9 (1981-86) 8 (RT group) and 9 (No-RT) 
Anti-estrogen therapy ER-pos patients randomized to 
+/- Oophrectomy (induced by RT(20Gy/5 
and 7.5 mg predninsolon in 2 years)  
No treatment 
Radiation (dose/fraction) 37.5Gy/16 55Gy/25 or 53Gy/22 
 RT after CMF 
(cyclus number) 
4 1 
 Anterior fields Chest wall 
Axillary  
Supraclavicular 
Electron: 
Chest wall 
Internal mammary nodes 
Photon: 
Axillary 
Supraclavicular 
Infraclavicular 
 Posterior fields Axillary boost Only if the max dose was not obtained 
by anterior treatment 
 Technology Cobalt-60 Linear accelerator  
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Supplementary Table 2. Distribution of clinicopathological parameters among patients from the study 
cohorts and the original BC and DBCG 82b trials. 
 
 
BC-trial  DBCG 82b-trial 
 
Study cohort Orignal study  Study cohort Orignal study 
 
N (%) N (%)  N (%) N (%) 
Patients (N) 145 (40%) 318 (100%)  83 (5%) 1708 (100%) 
Ovarian ablation 35 (24%) 88 (28%)  0 (0%) 0 (0%) 
Age          
 <41 41 (28%) 70 (22%)  15 (18%) 323 (19%) 
 41- 104 (72%) 246 (77%)  68 (82%) 1385 (81%) 
Unknown .  2 (0.6%)      
Tumor size (mm)          
 <21  40 (28%) 126 (40%)  24 (29%) 674 (39%) 
 21-50 82 (57%) 141 (44%)  46 (55%) 772 (45%) 
 >50 9 (6%) 11 (3%)  13 (16%) 234 (14%) 
 Unknown 14 (10%) 40 (13%)  0 (0%) 28 (2%) 
Lymph node status          
 Negative 0 (0%) 0 (0%)  0 (0%) 135 (8%) 
 1-3 positive 84 (58%) 183 (58%)  42 (51%) 1061 (62%) 
 >3 positive 49 (34%) 112 (35%)  41 (49%) 510 (30%) 
 Unknown 12 (8%) 23 (7%)  0 (0%) 2 (0.1%) 
Malignancy grade          
 Grade 1 16 (11%) 89 (28%)  10 (12%) *363 (25%) 
 Grade 2 51 (35%) 141 (44%)  47 (57%) *701 (48%) 
 Grade 3 55 (38%) 88 (28%)  23 (28%) *351 (24%) 
 Unknown 23 (16%) 0 (0%)  3 (4%) *46 (3%) 
 
* Ductal carcinomas only (N=1461) 
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Supplementary Figure 1. Flowchart for cohorts. 
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